Compare Gilead Sciences, Inc. (GILD) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Gilead Sciences, Inc. trades at $149.8 (market cap $182.40B), while Vanguard Dividend Appreciation Index Fund ETF trades at $238.22 (market cap $132.40B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Vanguard Dividend Appreciation Index Fund ETF for 133 Days on average.
| GILD | VIG | |
|---|---|---|
Market Cap | $182.40B | $132.40B |
Volume | 4,469,821 | 1,287,188 |
Sector | Health | — |
52-Week High | $155.80 | $246.61 |
52-Week Low | $116.74 | $210.70 |
Typical Hold Time | 111 Days | 133 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
VIG trades at $236.99, down 0.32% on the day, with a bullish technical signal from moving averages. The ETF focuses on dividend growth companies with at least 10 consecutive years of dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent quarterly dividend increased 7.5%, though year-to-date growth remains modest at 3.3%.
Outlook remains positive for long-term investors seeking dividend growth, with VIG averaging 10% annual returns since inception. Key risks include slower dividend growth pace and exclusion of high-yield stocks by design. The ETF's quality focus provides defensive characteristics but may lag during strong growth markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
